(TXG) 10X Genomics - Ratings and Ratios

10X Genomics Inc. (NASDAQ:TXG) is a pioneer in life science technology, delivering cutting-edge tools and platforms that enable researchers to analyze biological systems at unprecedented resolution. The companys product portfolio includes the Chromium, Chromium Connect, and Chromium Controller instruments, along with microfluidic chips, slides, reagents, and other consumables. These systems are designed to support single-cell analysis, a critical area of research that allows scientists to measure gene activity, study immune systems, and understand epigenetic states at the individual cell level.

The companys single-cell solutions are powered by its proprietary Chromium instruments, which support a range of applications. These include single-cell gene expression for mapping gene activity, single-cell immune profiling to study the immune system, and single-cell ATAC (Assay for Transposase Accessible Chromatin) solutions to analyze chromatin accessibility. Additionally, the company offers multiome ATAC + gene expression, enabling simultaneous analysis of RNA and chromatin in single cells. This integrated approach provides researchers with a more comprehensive understanding of cellular biology.

10X Genomics also offers the Visium platform, which allows researchers to study the spatial arrangement of biological molecules within tissues at high resolution. This spatial genomics capability is transformative for understanding disease mechanisms and tissue architecture. The companys Xenium platform further extends its capabilities into in situ analysis, providing additional tools for researchers to study biological systems in their natural context.

Founded in 2012 and headquartered in Pleasanton, California, 10X Genomics serves a diverse range of customers, including academic institutions, government agencies, biopharmaceutical companies, and biotechnology firms. The company, originally named 10X Technologies, rebranded as 10X Genomics in